Laboratory changes during dupilumab treatment for atopic dermatitis.

Introduction: Dupilumab is an IL-4 / IL-13 inhibitor monoclonal antibody approved for the treatment of moderate-to-severe atopic dermatitis (AD) with remarkable safety and efficacy profiles. However, former studies have reported an increase in serum eosinophils during treatment, with undetermined clinical significance.

The Objective: of this study is to evaluate changes in blood eosinophils and other laboratory parameters while on dupilumab.